Joslin Diabetes Center

Running trials

• Not yet recruiting

  Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

  NCT07683026· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Recruiting

  App-Based Certified Diabetes Education Therapy (AB-CDE)

  NCT07282639· Oregon Health and Science University· Source

• Recruiting

  Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

  NCT07142252· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Recruiting

  Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

  NCT07579702· Insulet Corporation· Source

• Recruiting

  Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

  NCT07521475· Insulet Corporation· Source

• Recruiting

  INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

  NCT07224321· Phase 2· Mannkind Corporation· Source

• Recruiting

  Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics

  NCT07271043· Joslin Diabetes Center· Source

• Recruiting

  Postnatal Exercise to Activate Baby's Brown Fat

  NCT07467694· Joslin Diabetes Center· Source

• Recruiting

  Exercise, Brain Activity, and Weight Maintenance

  NCT06511310· Joslin Diabetes Center· Source

• Recruiting

  A Study of GNTI-122 in Adults Recently Diagnosed With T1D

  NCT06919354· Phase 1· GentiBio, Inc· Source

• Recruiting

  Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

  NCT06790784· Phase 3· Jaeb Center for Health Research· Source

• Recruiting

  HLA Demographics Study in Adults With Type 1 Diabetes

  NCT06860516· GentiBio, Inc· Source

• Recruiting

  CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

  NCT06783309· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

• Active, not recruiting

  T1D Pregnancy & Me

  NCT06959316· Jaeb Center for Health Research· Source

• Recruiting

  Diabetes Body Project 2

  NCT07468188· Joslin Diabetes Center· Source

• Recruiting

  Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

  NCT06217302· Phase 3· Alessandro Doria· Source

• Active, not recruiting

  Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

  NCT06111586· Phase 2· Sanofi· Source

• Active, not recruiting

  Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

  NCT05904028· Phase 3· Jaeb Center for Health Research· Source

• Active, not recruiting

  Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

  NCT03929601· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Active, not recruiting

  Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

  NCT05743244· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Active, not recruiting

  Evaluation of Tonabersat for DME

  NCT05727891· Phase 2· Jaeb Center for Health Research· Source

• Active, not recruiting

  The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System

  NCT05754281· Joslin Diabetes Center· Source

• Active, not recruiting

  Multi-Site Eating Disorder Prevention Program for Type 1 Diabetes

  NCT05399446· Oslo University Hospital· Source

• Recruiting

  PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life

  NCT06141434· University of Colorado, Denver· Source

• Enrolling by invitation

  The Diabetes Prevention Program Outcomes Study AD/ADRD Project

  NCT05704309· Marinella Temprosa· Source

• Active, not recruiting

  Fenofibrate for Prevention of DR Worsening

  NCT04661358· Phase 3· Jaeb Center for Health Research· Source

• Active, not recruiting

  Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

  NCT04595474· Joslin Diabetes Center· Source

• Recruiting

  Kidney Precision Medicine Project

  NCT04334707· Icahn School of Medicine at Mount Sinai· Source

• Active, not recruiting

  A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

  NCT03811561· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Impact of Metabolic Health on Sperm Epigenetic Marks in Humans

  NCT03860558· Joslin Diabetes Center· Source

• Recruiting

  Type 1 Diabetes Extension Study

  NCT02734277· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Active, not recruiting

  Evaluating the Health Outcomes of the Joslin Why WAIT Program

  NCT01937845· Joslin Diabetes Center· Source

• Recruiting

  TrialNet Pathway to Prevention of T1D

  NCT00097292· University of South Florida· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 1 diabetes13 recruiting
• Type 2 diabetes5 recruiting
• Obesity3 recruiting
• Chronic kidney disease2 recruiting
• Alzheimer disease1 recruiting
• Diabetic eye disease1 recruiting
• Heart failure1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Completed

  Simplified Onboarding in Adults With Type 2 Diabetes

  NCT07070830· Insulet Corporation· Source

• Withdrawn

  SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

  NCT06719531· Medtronic MiniMed, Inc.· Source

• Completed

  Innovative Automated Insulin Delivery System for Type 2 Diabetes

  NCT06853990· Deka Research and Development· Source

• Completed

  Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

  NCT06865989· Insulet Corporation· Source

• Completed

  A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

  NCT06362265· Phase 1· Eli Lilly and Company· Source

• Completed

  A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

  NCT05901831· Phase 3· Bayer· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06045221· Phase 3· Eli Lilly and Company· Source

• Completed

  INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

  NCT05904743· Phase 4· Mannkind Corporation· Source

• Completed

  Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM

  NCT05714059· Medtronic MiniMed, Inc.· Source

• Completed

  Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes

  NCT05683392· Tandem Diabetes Care, Inc.· Source

• Completed

  Deprescribing of Diabetes Regimens in Long Term Care Residents With Alzheimer's

  NCT05535478· Joslin Diabetes Center· Source

• Completed

  A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

  NCT05514535· Phase 3· Novo Nordisk A/S· Source

• Completed

  Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)

  NCT05413239· Joslin Diabetes Center· Source

• Completed

  Omnipod 5 System Compared to Pump Therapy

  NCT05409131· Insulet Corporation· Source

• Completed

  A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

  NCT04929379· Phase 2· Alessandro Doria· Source

• Completed

  Afrezza® INHALE-1 Study in Pediatrics

  NCT04974528· Phase 3· Mannkind Corporation· Source

• Completed

  Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study

  NCT04409795· Phase 2/3· Joslin Diabetes Center· Source

• Completed

  Effects of a Single Bout of Exercise on Transcriptomics and Metabolomics in Adipose Tissue

  NCT04865965· Joslin Diabetes Center· Source

• Terminated

  IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

  NCT04524949· Phase 2· Imcyse SA· Source

• Completed

  A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

  NCT04279613· Phase 1· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Completed

  A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

  NCT04527107· Phase 2· Oxurion· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Completed

  Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

  NCT03895996· Phase 1/2· Avotres Inc.· Source

• Completed

  Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes

  NCT02328599· Ali Aminian· Source

• Completed

  Exercise Regulation of Human Adipose Tissue

  NCT03133156· Joslin Diabetes Center· Source

• Completed

  Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

  NCT01762046· Phase 1· Massachusetts General Hospital· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Type 1 diabetes48 works · 36 trials
• Diabetic eye disease14 works · 5 trials